In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sun Pharmaceutical Industries Ltd.

https://www.sunpharma.com/

Latest From Sun Pharmaceutical Industries Ltd.

Data Exclusivity Demand In EFTA-India Deal: Access, Licensing, Other Implications

The contentious issue of data exclusivity came to the fore during the European Free Trade Association's negotiations with India for a Free Trade Agreement. What are the arguments in support and against, including impact on compulsory and voluntary licensing?

Intellectual Property Policy

Data Exclusivity Demand In EFTA-India Deal: Access, Licensing, Other Implications

The contentious issue of data exclusivity came to the fore during the European Free Trade Association's negotiations with India for a Free Trade Agreement. What are the arguments in support and against, including impact on compulsory and voluntary licensing?

Policy Intellectual Property

Data Exclusivity Demand In EFTA-India Deal: Access, Licensing, Other Implications

The contentious issue of data exclusivity came to the fore during the European Free Trade Association's negotiations with India for a Free Trade Agreement. What are the arguments in support and against, including impact on compulsory and voluntary licensing?

Policy Intellectual Property

What’s In Store For Sun’s Key Specialty Drugs Including Melanoma Asset

An "uncontested market" in the neoadjuvant setting potentially awaits Sun’s partnered melanoma asset Nidlegy, while competition heats up for products like Cequa in the US. Scrip pieces together management commentary and analysts’ outlook on some of the key specialty therapies that India’s top-ranked drug maker is building out.

Commercial Business Strategies
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Generic Drugs
    • Specialty Pharmaceuticals
  • Other Names / Subsidiaries
    • Aditya Acquisition Company ltd
    • Caraco Pharmaceutical Laboratories, Ltd.
    • DUSA Pharmaceuticals, Inc.
    • InSite Vision, Inc.
    • JSC Biosintez
    • Ocular Technologies
    • Pola Pharma Inc.
    • Ranbaxy Laboratories Limited
    • Ranbaxy Solus
    • Solus Care
    • Sun Ophthalmics
    • Sun Pharma Global FZE
UsernamePublicRestriction

Register